a. Thrombin peptide Chrysalin stimulates healing of diabetic foot ulcers in a placebo-controlled phase I/II study. Fife C, Mader JT, Stone J, Brill L, Satterfield K, Norfleet A, Zwernemann A, Ryaby JT, Carney DH. Wound Repair Regen. 2007 Jan-Feb;15(1):23-34. doi: 10.1111/j.1524-475X.2006.00181.x.PMID: 17244316 https://pubmed.ncbi.nlm.nih.gov/17244316/
b. Could rusalatide acetate be the future drug of choice for diabetic foot ulcers and fracture repair? Carney DH, Olszewska-Pazdrak B.Expert Opin Pharmacother. 2008 Oct;9(15):2717-26. doi: 10.1517/14656566.9.15.2717.PMID: 18803458 Review. https://pubmed.ncbi.nlm.nih.gov/18803458/
c. Thrombin peptide TP508 stimulates cellular events leading to angiogenesis, revascularization, and repair of dermal and musculoskeletal tissues. Ryaby JT, Sheller MR, Levine BP, Bramlet DG, Ladd AL, Carney DH. J Bone Joint Surg Am. 2006 Nov;88 Suppl 3:132-9. doi: 10.2106/JBJS.F.00892.PMID: 17079379 Review. https://pubmed.ncbi.nlm.nih.gov/17079379/
The TP508 Solution for Tissue Repair
Clinical Trials – Tissue Repair
About Us
Chrysalis BioTherapeutics, Inc. is committed to helping improve people’s lives through innovation.
Let’s Socialize
Popular Post
Chrysalis BioTherapeutics, Inc. Announces Collaboration with NIAID to Evaluate Chrysalin® for the Treatment of Cutaneous Radiation Injury
GALVESTON, Texas–(BUSINESS WIRE)–Chrysalis BioTherapeutics, Inc., a clinical stage biopharmaceutical company developing Chrysalin as
Chrysalis BioTherapeutics Selected to Present at Respiratory Innovation Summit
GALVESTON, Texas–(BUSINESS WIRE)–Chrysalis BioTherapeutics today announced it was selected to participate in the
Chrysalis Receives FDA Approval to Initiate Clinical Trials with Chrysalin™ (TP508)
GALVESTON, Texas–(BUSINESS WIRE)–Chrysalis BioTherapeutics, Inc. announced today that the US Food and Drug